Incanthera acquires Swiss lectin skincare brand Énielle
Incanthera (AIM:INC) agreed to acquire Énielle, a Swiss lectin-based skincare brand, in an all-equity deal structured as up to 54 million new shares at 2p each. Alongside the acquisition, the company secured a £250,000 convertible loan facility from its incoming chief executive, providing near-term working capital as the transaction completes. The announcement sent the shares up 41.18% to 1.8501p.
The deal marks a strategic pivot for Incanthera, adding a commercial skincare asset built around lectin science to its existing pipeline. The equity consideration structure preserves cash while aligning the vendor's interests with the enlarged group's performance.
Crism Therapeutics wins £896,000 Innovate UK grant for glioblastoma trial
Crism Therapeutics Corporation (AIM:CRTX) secured a £896,088 non-dilutive grant from Innovate UK, covering 70% of a £1.28 million project to fund Part 1 of an open-label Phase 2 registration-grade trial of its irinotecan-ChemoSeed therapy in surgically resectable glioblastoma. The grant removes a significant portion of the trial's near-term funding burden without shareholder dilution. Shares edged up 1.64% to 11.18p on the news.
ChemoSeed is Crism's localised drug-delivery platform designed to improve chemotherapy targeting in brain tumours. Securing Innovate UK backing at this stage lends the programme additional validation as it advances toward registration-grade data.
Eco Animal Health renews credit facilities on improved terms
Eco Animal Health Group (AIM:EAH) renewed its committed £10 million revolving credit facility with National Westminster Bank on more favourable terms and extended its £5 million overdraft facility. The refinancing strengthens the group's liquidity headroom without altering its capital structure, and the shares ticked up 0.52% to 93.48p on the announcement.
